低收入国家药物创新的新模式。 - Suppr

Suppr

超能文献

New models for pharmaceutical innovation in low-income countries.

作者信息

Ardal Christine, Iversen Johanne Helene, Myhr Kirsten

机构信息

Global Health Unit, Norwegian Knowledge Centre for Health Services, Norway.

出版信息

Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.

DOI:10.4045/tidsskr.11.0658

PMID:22016131

Abstract

摘要

相似文献

New models for pharmaceutical innovation in low-income countries.

Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.

Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.

Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14.

The role of academic institutions in the development of drugs for rare and neglected diseases.

Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4.

A new era of hope for the world's most neglected diseases.

PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8.

The European rare diseases therapeutic initiative.

PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.

Uncommon ventures launch to tackle uncommon diseases.

Nat Med. 2013 Aug;19(8):950-1. doi: 10.1038/nm0813-950.

Jumpstarting research into neglected diseases.

Cell. 2006 Nov 3;127(3):443-5. doi: 10.1016/j.cell.2006.10.022.

PPPs succeeding in tackling neglected diseases.

Nat Rev Drug Discov. 2005 Oct;4(10):796-7. doi: 10.1038/nrd1868.

Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.

Drug Discov Today. 2013 Nov;18(21-22):1043-51. doi: 10.1016/j.drudis.2013.08.006. Epub 2013 Aug 19.

In silico repositioning of approved drugs for rare and neglected diseases.

Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

New models for pharmaceutical innovation in low-income countries.

Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658.

Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.

Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14.

The role of academic institutions in the development of drugs for rare and neglected diseases.

Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Epub 2012 Jul 4.

A new era of hope for the world's most neglected diseases.

PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8.

The European rare diseases therapeutic initiative.

PLoS Med. 2005 Sep;2(9):e243. doi: 10.1371/journal.pmed.0020243. Epub 2005 Aug 23.

Uncommon ventures launch to tackle uncommon diseases.

Nat Med. 2013 Aug;19(8):950-1. doi: 10.1038/nm0813-950.

Jumpstarting research into neglected diseases.

Cell. 2006 Nov 3;127(3):443-5. doi: 10.1016/j.cell.2006.10.022.

PPPs succeeding in tackling neglected diseases.

Nat Rev Drug Discov. 2005 Oct;4(10):796-7. doi: 10.1038/nrd1868.

Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.

Drug Discov Today. 2013 Nov;18(21-22):1043-51. doi: 10.1016/j.drudis.2013.08.006. Epub 2013 Aug 19.

In silico repositioning of approved drugs for rare and neglected diseases.

Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Epub 2011 Mar 1.